<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455491</url>
  </required_header>
  <id_info>
    <org_study_id>ARI-XC221-02</org_study_id>
    <nct_id>NCT03455491</nct_id>
  </id_info>
  <brief_title>Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections</brief_title>
  <official_title>Multicenter Double-blinded Placebo-Controlled Parallel-Group Randomized Clinical Trial of Efficacy, Safety and Choice of an Optimum Dose of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PHARMENTERPRISES LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PHARMENTERPRISES LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter double-blinded, randomized, placebo-controlled, parallel-group comparative
      Phase II clinical study to assess safety, tolerability, efficacy and optimal dose of XC221
      vs. placebo in patients with uncomplicated influenza or other ARVI during a 3-day treatment.

      The primary objective of the study is to demonstrate the difference in time before the onset
      of a sustained improvement in clinical symptoms according to the Modified Jackson Scale for
      ARVI and to determine the optimal dose of XC221 in the treatment of influenza and other ARVI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      11 Russian centers were planned for participation in this study. The study consists of three
      periods: screening, treatment and follow-up.

      All eligible patients will be randomized into 3 groups (groups A, B and C) in a 1:1:1 ratio:

      Group A - XC221 100 mg daily (40 patients); Group B - XC221 200 mg daily (40 patients); Group
      C - Placebo (40 patients).

      During the treatment period (3 days), patients will receive XC221 / placebo daily on a
      background of standard symptomatic therapy. The follow-up period lasts for 11 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Actual">June 28, 2018</completion_date>
  <primary_completion_date type="Actual">June 28, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Blinding will carried out by using Placebo equivalent to XC221 tablets without active substance and the corresponding labeling of the study drug.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Sustained Improvement in Clinical Symptoms Based on Modified Jackson Scale for ARVI</measure>
    <time_frame>From the time of randomization up to Day 14</time_frame>
    <description>The time before the onset of sustained improvement in clinical symptoms according to the Modified Jackson Scale (no more than 1 point for each symptom), measured in hours from the moment of the first dose of the drug.
Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Body Temperature Normalization</measure>
    <time_frame>From the time of randomization assessed up to Day 14</time_frame>
    <description>Time to body temperature normalization since treatment initiation, measured in hours (normalization is regarded as setting of body temperature below 37°C without elevation above these values)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Complications</measure>
    <time_frame>From the time of randomization up to Day 14</time_frame>
    <description>The percentage of patients with complications of influenza/acute viral URI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Area Under the Curve &quot;Modified Jackson Scale Score&quot; During 3-day Therapy</measure>
    <time_frame>From randomization up to 3 days of treatment</time_frame>
    <description>Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Acute Respiratory Viral Infections</condition>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>XC221 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XC221 100 mg orally.
1 tablet of XC221 100 mg +1 tablet of Placebo 100 mg (in total 2 tablets) once daily during 3 days of treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XC221 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo orally. 2 tablets of Placebo 100 mg once daily during 3 days of treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XC221 100 mg</intervention_name>
    <description>once daily during 3 days.</description>
    <arm_group_label>XC221 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XC221 200 mg</intervention_name>
    <description>once daily during 3 days.</description>
    <arm_group_label>XC221 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily during 3 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women aged 18 to 45 years (inclusively).

          2. Clinically diagnosed influenza or ARVI.

          3. Patient's body temperature ≥37.5ºС and at least 1 symptom from Modified Jackson Scale
             estimated more than 2 points.

          4. Uncomplicated course of influenza or ARVI based on clinical estimations.

          5. The first 36 hours from the beginning of symptoms of influenza or ARVI.

          6. Women of reproductive age (who are not in menopause and who have not undergone
             surgical sterilization) and men who have sexual activity should use a reliable method
             of contraception (acceptable methods of contraception in this study are: intrauterine
             devices, oral contraceptives, contraceptive patch, long-acting injectable
             contraceptives, a double barrier method (condom and diaphragm with spermicide)
             throughout the study period.

          7. Compliance with the treatment regimen, visits and laboratory examinations provided by
             the protocol.

          8. Signed Informed Consent Form.

        Exclusion Criteria:

          1. Existence of complications of influenza or ARVI (including the presence / development
             of bacterial infection).

          2. Hypersensitivity to excipients of the drug XC221 or placebo.

          3. Antiviral medications in 7 days prior to screening (antiviral agents, interferons and
             interferon inducers, drugs that have immunomodulating action) or anti-infective agents
             of systemic or local action.

          4. Severe infection with signs of cardiovascular insufficiency development and other
             manifestations of infectious-toxic shock, as well as with the presence of
             neuroinfection syndrome (encephalic and meningoencephalic reactions,
             polyradiculoneuritis, neuritis).

          5. Signs of the development of viral pneumonia (the presence of two or more of the
             following symptoms): dyspnea, chest pain when coughing, systemic cyanosis, dullness of
             percussion sound with a symmetrical evaluation of the upper and lower sections of the
             lungs).

          6. Infectious diseases during the last week before including into the study.

          7. History of bronchial asthma.

          8. History of increased convulsive activity.

          9. Severe, decompensated or unstable somatic diseases (any diseases or conditions that
             are life-threatening or may worsen the patient's prognosis, and make him/her
             ineligible for the clinical study).

         10. History of oncological diseases, HIV, tuberculosis.

         11. Diabetes mellitus.

         12. Drug or alcohol abuse.

         13. Participation in any other clinical trial in the last 90 days.

         14. Pregnancy or lactation.

         15. Military or prison populations.

         16. Impossibility or inability to comply with the study procedures.

         17. A member of the investigator's family or other person interested in the results of the
             study.

         18. Abnormal laboratory results, which, according to the study doctor, interfere with the
             patient's inclusion in the study.

         19. History of renal insufficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City Clinical Hospital №9</name>
      <address>
        <city>Izhevsk</city>
        <zip>426063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuban State Medical University</name>
      <address>
        <city>Krasnodar</city>
        <zip>350063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital №1 n.a. Semashko</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryazan State Medical University n.a. Pavlov</name>
      <address>
        <city>Ryazan'</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Prevention and Fight about AIDS and Infectious Diseases</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Consulting and Diagnostic Center with out-patient help of the Administration of the President of the Russian Federation</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Influenza</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital №40 of Kurortny District</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mordovia State Medical University n.a. N.P.Ogarev, Clinical site - Republic Infectious Clinical Hospital</name>
      <address>
        <city>Saransk</city>
        <zip>430024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volgograd State Medical University, Clinical site - Infectious Regional Clinical Hospital № 1</name>
      <address>
        <city>Volgograd</city>
        <zip>400131</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Сlinical Hospital №3</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <results_first_submitted>February 18, 2019</results_first_submitted>
  <results_first_submitted_qc>October 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 4, 2019</results_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT03455491/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients receiving both in- and outpatient treatment could be enrolled.</recruitment_details>
      <pre_assignment_details>A total of 121 patients were screened to participate in the trial; one patient was withdrawn at screening.
120 patients were randomly assigned into 3 groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>XC221 100 mg orally.
1 tablet of XC221 100 mg +1 tablet of Placebo 100 mg (in total 2 tablets) once daily during 3 days of treatment period
XC221 100 mg: once daily during 3 days.</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
XC221 200 mg: once daily during 3 days.</description>
        </group>
        <group group_id="P3">
          <title>Group C</title>
          <description>Placebo orally. 2 tablets of Placebo 100 mg once daily during 3 days of treatment period
Placebo: once daily during 3 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>XC221 100 mg orally.
1 tablet of XC221 100 mg +1 tablet of Placebo 100 mg (in total 2 tablets) once daily during 3 days of treatment period
XC221 100 mg: once daily during 3 days.</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
XC221 200 mg: once daily during 3 days.</description>
        </group>
        <group group_id="B3">
          <title>Group C</title>
          <description>Placebo orally. 2 tablets of Placebo 100 mg once daily during 3 days of treatment period
Placebo: once daily during 3 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="7.3"/>
                    <measurement group_id="B2" value="31.1" spread="7.1"/>
                    <measurement group_id="B3" value="32.2" spread="8.1"/>
                    <measurement group_id="B4" value="31.1" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence of confirmed viral infection by PCR</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Viral infection confirmed by PCR</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No viral infection confirmed by PCR</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Sustained Improvement in Clinical Symptoms Based on Modified Jackson Scale for ARVI</title>
        <description>The time before the onset of sustained improvement in clinical symptoms according to the Modified Jackson Scale (no more than 1 point for each symptom), measured in hours from the moment of the first dose of the drug.
Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.</description>
        <time_frame>From the time of randomization up to Day 14</time_frame>
        <population>Full Analysis Set (FAS) population</population>
        <group_list>
          <group group_id="O1">
            <title>XC221 100 mg</title>
            <description>XC221 100 mg orally.
1 tablet of XC221 100 mg +1 tablet of Placebo 100 mg (in total 2 tablets) once daily during 3 days of treatment period
XC221 100 mg: once daily during 3 days.</description>
          </group>
          <group group_id="O2">
            <title>XC221 200 mg</title>
            <description>XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
XC221 200 mg: once daily during 3 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo orally. 2 tablets of Placebo 100 mg once daily during 3 days of treatment period
Placebo: once daily during 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Sustained Improvement in Clinical Symptoms Based on Modified Jackson Scale for ARVI</title>
          <description>The time before the onset of sustained improvement in clinical symptoms according to the Modified Jackson Scale (no more than 1 point for each symptom), measured in hours from the moment of the first dose of the drug.
Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.</description>
          <population>Full Analysis Set (FAS) population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.38" lower_limit="53.31" upper_limit="73.53"/>
                    <measurement group_id="O2" value="67.75" lower_limit="53.69" upper_limit="73.87"/>
                    <measurement group_id="O3" value="69.64" lower_limit="63.56" upper_limit="88.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3541</p_value>
            <method>Gekhan-Wilcoxon test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Body Temperature Normalization</title>
        <description>Time to body temperature normalization since treatment initiation, measured in hours (normalization is regarded as setting of body temperature below 37°C without elevation above these values)</description>
        <time_frame>From the time of randomization assessed up to Day 14</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>XC221 100 mg</title>
            <description>XC221 100 mg orally.
1 tablet of XC221 100 mg +1 tablet of Placebo 100 mg (in total 2 tablets) once daily during 3 days of treatment period
XC221 100 mg: once daily during 3 days.</description>
          </group>
          <group group_id="O2">
            <title>XC221 200 mg</title>
            <description>XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
XC221 200 mg: once daily during 3 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo orally. 2 tablets of Placebo 100 mg once daily during 3 days of treatment period
Placebo: once daily during 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Body Temperature Normalization</title>
          <description>Time to body temperature normalization since treatment initiation, measured in hours (normalization is regarded as setting of body temperature below 37°C without elevation above these values)</description>
          <population>FAS population</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.08" spread="52.85"/>
                    <measurement group_id="O2" value="52.26" spread="34.08"/>
                    <measurement group_id="O3" value="61.40" spread="38.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3597</p_value>
            <method>Gekhan-Wilcoxon test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Complications</title>
        <description>The percentage of patients with complications of influenza/acute viral URI</description>
        <time_frame>From the time of randomization up to Day 14</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>XC221 100 mg</title>
            <description>XC221 100 mg orally.
1 tablet of XC221 100 mg +1 tablet of Placebo 100 mg (in total 2 tablets) once daily during 3 days of treatment period
XC221 100 mg: once daily during 3 days.</description>
          </group>
          <group group_id="O2">
            <title>XC221 200 mg</title>
            <description>XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
XC221 200 mg: once daily during 3 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo orally. 2 tablets of Placebo 100 mg once daily during 3 days of treatment period
Placebo: once daily during 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Complications</title>
          <description>The percentage of patients with complications of influenza/acute viral URI</description>
          <population>FAS population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No complications</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>With complications</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Area Under the Curve &quot;Modified Jackson Scale Score&quot; During 3-day Therapy</title>
        <description>Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.</description>
        <time_frame>From randomization up to 3 days of treatment</time_frame>
        <population>FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>XC221 100 mg</title>
            <description>XC221 100 mg orally.
1 tablet of XC221 100 mg +1 tablet of Placebo 100 mg (in total 2 tablets) once daily during 3 days of treatment period
XC221 100 mg: once daily during 3 days.</description>
          </group>
          <group group_id="O2">
            <title>XC221 200 mg</title>
            <description>XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
XC221 200 mg: once daily during 3 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo orally. 2 tablets of Placebo 100 mg once daily during 3 days of treatment period
Placebo: once daily during 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Area Under the Curve &quot;Modified Jackson Scale Score&quot; During 3-day Therapy</title>
          <description>Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.</description>
          <population>FAS population</population>
          <units>Ln(units_on_a_scale*sec)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="0.4"/>
                    <measurement group_id="O2" value="14.6" spread="0.4"/>
                    <measurement group_id="O3" value="14.7" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4551</p_value>
            <method>ANOVA</method>
            <method_desc>one-way ANOVA</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>XC221 100 mg orally.
1 tablet of XC221 100 mg +1 tablet of Placebo 100 mg (in total 2 tablets) once daily during 3 days of treatment period
XC221 100 mg: once daily during 3 days.</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
XC221 200 mg: once daily during 3 days.</description>
        </group>
        <group group_id="E3">
          <title>Group C</title>
          <description>Placebo orally. 2 tablets of Placebo 100 mg once daily during 3 days of treatment period
Placebo: once daily during 3 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Basophilia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Tickling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Increased nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Increased hoarseness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Tickering</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Strengthening rhinorrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Increased sneezing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Tearing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epigastric pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Loose stools</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Chill increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Periodic temperature rise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fever increase</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Strengthening ailments</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Labial herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Strengthening myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Strengthening headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Strengthening cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>CEO Vladimir Nebolsin</name_or_title>
      <organization>PHARMENTERPRISES LLC</organization>
      <phone>+7 (985) 728-75-72</phone>
      <email>ph@pharmenterprises.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

